| MeSH term | MeSH ID | Detail |
|---|---|---|
| Bronchiolitis | D001988 | 6 associated lipids |
| Boutonneuse Fever | D001907 | 5 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Blister | D001768 | 16 associated lipids |
| Bites, Human | D001734 | 2 associated lipids |
| Birth Weight | D001724 | 23 associated lipids |
| Bartonella Infections | D001474 | 3 associated lipids |
| Bacterial Infections | D001424 | 21 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Van Bambeke F et al. | Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. | 1996 | Eur. J. Pharmacol. | pmid:8957238 |
| Montenez JP et al. | Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. | 1996 | Eur. J. Pharmacol. | pmid:8957239 |
| Prescott LM | Macrolides, azalides, and streptogrammins. | 1996 | J Int Assoc Physicians AIDS Care | pmid:11363516 |
| Currier J | Progress report: prophylaxis and therapy for MAC. | 1996 | AIDS Clin Care | pmid:11363599 |
| Old drug approved for MAC prevention. | 1996 | AIDS Alert | pmid:11363659 | |
| Bertoni G et al. | Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. | 1996 | Am. J. Gastroenterol. | pmid:8607489 |
| Di Mario F et al. | Azithromycin for the cure of Helicobacter pylori infection. | 1996 | Am. J. Gastroenterol. | pmid:8607490 |
| Dupont C et al. | Microbiological findings about pulmonary cryptosporidiosis in two AIDS patients. | 1996 | J. Clin. Microbiol. | pmid:8748314 |
| Wildfeuer A et al. | Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. | 1996 | Antimicrob. Agents Chemother. | pmid:8787883 |
| Okada T et al. | [Pharmacokinetic and clinical evaluations of azithromycin in the pediatric field]. | 1996 | Jpn J Antibiot | pmid:8988414 |
| Ishida Y et al. | [Pharmacokinetic and clinical evaluation of azithromycin in pediatric infections]. | 1996 | Jpn J Antibiot | pmid:8988415 |
| Ohtsuka Y et al. | [Pharmacokinetic and clinical studies on azithromycin in children]. | 1996 | Jpn J Antibiot | pmid:8988416 |
| Cammarota G et al. | Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971300 |
| Kuznetsova SM | ["Sumamed in the treatment of urogenital infections"]. | 1996 | Antibiot. Khimioter. | pmid:8929115 |
| Skripkin IuK et al. | [The problem of diagnosis and treatment of urogenital chlamydiosis in Russia]. | 1996 | Antibiot. Khimioter. | pmid:8929120 |
| Amsden GW | Erythromycin, clarithromycin, and azithromycin: are the differences real? | 1996 Jan-Feb | Clin Ther | pmid:8851453 |
| Preac Mursic V et al. | Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis. | 1996 Jan-Feb | Infection | pmid:8852456 |
| Baradaran-Dilmaghani R and Stanek G | In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. | 1996 Jan-Feb | Infection | pmid:8852472 |
| Strle F et al. | Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. | 1996 Jan-Feb | Infection | pmid:8852473 |
| Fontán PA et al. | Haemophilus influenzae type b exoproducts induce chemotaxis and macrolide antibiotic release by human polymorphonuclear leukocytes. | 1996 Jan-Feb | Chemotherapy | pmid:8751269 |
| Ehret JM et al. | A clinical isolate of Neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin. | 1996 Jul-Aug | Sex Transm Dis | pmid:8836018 |
| Lane G | Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin. | 1996 Jul-Aug | Ann Pharmacother | pmid:8826581 |
| Diculencu D et al. | [The postantibiotic effect of azithromycin on respiratory pathogens]. | 1996 Jul-Dec | Rev Med Chir Soc Med Nat Iasi | pmid:9455450 |
| Carlin EM and Barton SE | Azithromycin as the first-line treatment of non-gonococcal urethritis (NGU): a study of follow-up rates, contact attendance and patients' treatment preference. | 1996 May-Jun | Int J STD AIDS | pmid:8799780 |
| Shanks GD et al. | Azithromycin prophylaxis prevents epidemic dysentery. | 1996 May-Jun | Trans. R. Soc. Trop. Med. Hyg. | pmid:8758091 |
| Adam D et al. | Re: A. Bauernfeind et al.: Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens (Infection 23 [1995] 316-321) | 1996 May-Jun | Infection | pmid:8811372 |
| Vranes J | Effect of subinhibitory concentrations of ceftazidime, ciprofloxacin, and azithromycin on the hemagglutination and adherence of uropathogenic Escherichia coli strains. | 1996 May-Jun | Chemotherapy | pmid:8983884 |
| Ichimiya T et al. | The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. | 1996 May-Jun | Chemotherapy | pmid:8983885 |
| Galova K et al. | Multicenter randomized study of two once daily regimens in the initial management of community-acquired respiratory tract infections in 163 children: azithromycin versus ceftibuten. | 1996 May-Jun | Chemotherapy | pmid:8983893 |
| Burke SM | Azithromycin: only once a day. | 1996 May-Jun | MCN Am J Matern Child Nurs | pmid:8857402 |
| Ripa S et al. | A linear model for the pharmacokinetics of azithromycin in healthy volunteers. | 1996 Nov-Dec | Chemotherapy | pmid:8957574 |
| D'Amico R | ICAAC update on opportunistic infections. | 1996 Nov-Dec | Posit Aware | pmid:11363974 |
| Wendel TD | 1-day azithromycin was as effective as 7-day doxycycline for nongonococcal urethritis syndrome in men. | 1996 Nov-Dec | ACP J. Club | pmid:8912627 |
| Peeling RW and Brunham RC | Chlamydiae as pathogens: new species and new issues. | 1996 Oct-Dec | Emerging Infect. Dis. | pmid:8969247 |
| Biebuyck XA | Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group. | 1996 Sep-Oct | J. Int. Med. Res. | pmid:8895044 |
| New DL et al. | Vertically transmitted babesiosis. | 1997 | J. Pediatr. | pmid:9255211 |
| Rodvold KA et al. | Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. | 1997 | Antimicrob. Agents Chemother. | pmid:9174209 |
| Tarlow MJ et al. | Future indications for macrolides. | 1997 | Pediatr. Infect. Dis. J. | pmid:9109159 |
| Dawson CR et al. | A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. | 1997 | Clin. Infect. Dis. | pmid:9114186 |
| Brown BA et al. | Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. | 1997 | Clin. Infect. Dis. | pmid:9142801 |
| Littlewood-Evans AJ et al. | Effect of combination therapy of rifampicin and azithromycin on TNF levels during a rat model of chronic osteomyelitis. | 1997 | J. Antimicrob. Chemother. | pmid:9145822 |
| Caselli M et al. | Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. | 1997 | Eur J Gastroenterol Hepatol | pmid:9031898 |
| Arévalo Morles C et al. | Donovanosis: treatment with azithromycin. | 1997 | Int J STD AIDS | pmid:9043983 |
| Fuchs PC et al. | Effect of minor pH changes on the in-vitro activity of azithromycin and clarithromycin. | 1997 | J. Antimicrob. Chemother. | pmid:9044039 |
| Tursi A et al. | What is the best azithromycin-based therapy for Helicobacter pylori infection? | 1997 | J. Antimicrob. Chemother. | pmid:9044040 |
| Pendland SL et al. | Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones. | 1997 | J. Clin. Microbiol. | pmid:9350781 |
| Leri O et al. | [Effects of the triple therapy in the eradication of Helicobacter pylori: comparison of 3 different antibiotics]. | 1997 | Clin Ter | pmid:9528197 |
| Rajyaguru JM and Muszynski MJ | Enhancement of Burkholderia cepacia antimicrobial susceptibility by cationic compounds. | 1997 | J. Antimicrob. Chemother. | pmid:9338485 |
| Buehring I et al. | Chronic sinusitis refractory to standard management in patients with humoral immunodeficiencies. | 1997 | Clin. Exp. Immunol. | pmid:9328124 |
| Odenholt I et al. | Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase. | 1997 | Antimicrob. Agents Chemother. | pmid:9371360 |